You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBumetanide
Accession NumberDB00887  (APRD00294)
TypeSmall Molecule
GroupsApproved
DescriptionA sulfamyl diuretic. [PubChem]
Structure
Thumb
Synonyms
3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
3-Butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
3-Butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
3-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid
Bumetanida
Bumetanidum
External Identifiers
  • a684051
  • CS 380
  • Ro 10-6338
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bumetanidetablet.5 mg/1oralEdenbridge Pharmaceuticals, LLC2015-10-15Not applicableUs
Bumetanidetablet1 mg/1oralEdenbridge Pharmaceuticals, LLC2015-10-15Not applicableUs
Bumetanidetablet2 mg/1oralEdenbridge Pharmaceuticals, LLC2015-10-15Not applicableUs
Burinex - Tab 2mgtablet2 mgoralLeo Pharma Inc1996-12-312004-07-23Canada
Burinex Tab 1mgtablet1 mgoralLeo Pharma Inc1993-12-31Not applicableCanada
Burinex Tab 5mgtablet5 mgoralLeo Pharma Inc1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bumetanidetablet1 mg/1oralPhysicians Total Care, Inc.2009-02-16Not applicableUs
Bumetanidetablet1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-16Not applicableUs
Bumetanidetablet.5 mg/1oralCarilion Materials Management2007-10-16Not applicableUs
Bumetanidetablet1 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-10-16Not applicableUs
Bumetanidetablet.5 mg/1oralTeva Pharmaceuticals USA Inc2007-10-16Not applicableUs
Bumetanidetablet1 mg/1oralCardinal Health2011-04-29Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousCardinal Health2009-01-27Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
Bumetanidetablet1 mg/1oralAvera Mc Kennan Hospital2015-03-26Not applicableUs
Bumetanidetablet2 mg/1oralAv Kare, Inc.2015-01-26Not applicableUs
Bumetanidetablet1 mg/1oralEon Labs, Inc.1996-11-21Not applicableUs
Bumetanidetablet.5 mg/1oralPhysicians Total Care, Inc.2000-11-29Not applicableUs
Bumetanidetablet2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-16Not applicableUs
Bumetanidetablet1 mg/1oralCarilion Materials Management1996-11-21Not applicableUs
Bumetanidetablet.5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-10-16Not applicableUs
Bumetanidetablet1 mg/1oralTeva Pharmaceuticals USA Inc2007-10-16Not applicableUs
Bumetanidetablet1 mg/1oralSt Marys Medical Park Pharmacy2014-05-22Not applicableUs
Bumetanideinjection, solution.25 mg/mLintramuscular; intravenousCardinal Health2011-11-16Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
Bumetanidetablet2 mg/1oralAvera Mc Kennan Hospital2015-03-13Not applicableUs
Bumetanidetablet1 mg/1oralUnit Dose Services2007-10-16Not applicableUs
Bumetanidetablet2 mg/1oralEon Labs, Inc.1996-11-21Not applicableUs
Bumetanidetablet2 mg/1oralAvera Mc Kennan Hospital2015-09-11Not applicableUs
Bumetanidetablet2 mg/1oralPhysicians Total Care, Inc.2006-12-13Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
Bumetanidetablet2 mg/1oralSt Marys Medical Park Pharmacy2014-08-20Not applicableUs
Bumetanidetablet.5 mg/1oralAv Kare, Inc.2015-01-26Not applicableUs
Bumetanidetablet2 mg/1oralTeva Pharmaceuticals USA Inc2007-10-16Not applicableUs
Bumetanideinjection, solution.25 mg/mLintranodal; intravenousCardinal Health2011-11-16Not applicableUs
Bumetanidetablet1 mg/1oralAidarex Pharmaceuticals LLC2007-10-16Not applicableUs
Bumetanidetablet2 mg/1oralUnit Dose Services2007-10-16Not applicableUs
Bumetanideinjection, solution.25 mg/mLintramuscular; intravenousHospira, Inc.1994-10-31Not applicableUs
Bumetanidetablet1 mg/1oralAvera Mc Kennan Hospital2015-09-28Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousCardinal Health1995-03-01Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
Bumetanidetablet1 mg/1oralbryant ranch prepack2007-10-16Not applicableUs
Bumetanidetablet1 mg/1oralAv Kare, Inc.2015-01-26Not applicableUs
Bumetanidetablet.5 mg/1oralEon Labs, Inc.1996-11-21Not applicableUs
Bumetanideinjection, solution.25 mg/mLintramuscular; intravenousCardinal Health2011-11-16Not applicableUs
Bumetanidetablet2 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-10-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BumexF. Hoffmann-La Roche Ltd.
BurinexF. Hoffmann-La Roche Ltd.
FordiuranLEO Pharma A/S
LunetoronDaiichi Sankyo
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0Y2S3XUQ5H
CAS number28395-03-1
WeightAverage: 364.416
Monoisotopic: 364.10929245
Chemical FormulaC17H20N2O5S
InChI KeyInChIKey=MAEIEVLCKWDQJH-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
IUPAC Name
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
SMILES
CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylethers
Direct ParentDiphenylethers
Alternative Parents
Substituents
  • Diphenylether
  • Diaryl ether
  • Aminobenzenesulfonamide
  • Benzenesulfonamide
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Phenylalkylamine
  • Substituted aniline
  • Benzoyl
  • Secondary aliphatic/aromatic amine
  • Aniline
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.
PharmacodynamicsBumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect. Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).
Mechanism of actionBumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis.
Related Articles
AbsorptionBumetanide is completely absorbed (80%), and the absorption is not altered when taken with food. Bioavailability is almost complete.
Volume of distributionNot Available
Protein binding97%
Metabolism

45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain.

Route of eliminationOral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Biliary excretion of Bumex amounted to only 2% of the administered dose.
Half life60-90 minutes
Clearance
  • 0.2 – 1.1 mL/min/kg [preterm and full-term neonates with respiratory disorders]
  • 2.17 mL/min/kg [neonates receiving bumetanide for volume overload]
  • 1.8 +/- 0.3 mL/min/kg [geriatric subjects]
  • 2.9 +/- 0.2 mL/min/kg [younger subjects]
ToxicityOverdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bumetanide Action PathwayDrug actionSMP00088
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier-0.6636
Caco-2 permeable-0.6492
P-glycoprotein substrateNon-substrate0.509
P-glycoprotein inhibitor INon-inhibitor0.8765
P-glycoprotein inhibitor IINon-inhibitor0.8103
Renal organic cation transporterNon-inhibitor0.8966
CYP450 2C9 substrateNon-substrate0.6368
CYP450 2D6 substrateNon-substrate0.7656
CYP450 3A4 substrateNon-substrate0.6059
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7344
Ames testNon AMES toxic0.6794
CarcinogenicityNon-carcinogens0.7294
BiodegradationNot ready biodegradable0.9837
Rat acute toxicity1.8148 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.8591
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Validus pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Sandoz inc
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular; intravenous.25 mg/mL
Injection, solutionintramuscular; intravenous.25 mg/mL
Injection, solutionintranodal; intravenous.25 mg/mL
Tabletoral.5 mg/1
Tabletoral1 mg/1
Tabletoral2 mg/1
Tabletoral2 mg
Tabletoral1 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Bumex 2 mg tablet1.65USD tablet
Bumetanide 2 mg tablet1.04USD tablet
Bumex 1 mg tablet0.98USD tablet
Bumex 0.5 mg tablet0.7USD tablet
Bumetanide 1 mg tablet0.51USD tablet
Bumetanide 0.5 mg tablet0.38USD tablet
Bumetanide 0.25 mg/ml vial0.25USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230-231Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik Produktionsaktieselskab, Denmark.
water solubility>20 mg/mL (in base)Not Available
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0257 mg/mLALOGPS
logP3.44ALOGPS
logP2.42ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.69ChemAxon
pKa (Strongest Basic)2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.72 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity95.78 m3·mol-1ChemAxon
Polarizability37.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik
Produktionsaktieselskab, Denmark.

General ReferencesNot Available
External Links
ATC CodesC03EB02C03CB02C03CA02
AHFS Codes
  • 40:28.08
PDB EntriesNot Available
FDA labelDownload (206 KB)
MSDSDownload (72.8 KB)
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Bumetanide.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Bumetanide.
AcebutololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acebutolol.
AceclofenacAceclofenac may decrease the diuretic activities of Bumetanide.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Bumetanide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bumetanide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Bumetanide.
AdapaleneAdapalene may decrease the diuretic activities of Bumetanide.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Bumetanide.
AlclometasoneAlclometasone may increase the hypokalemic activities of Bumetanide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.
AldosteroneAldosterone may increase the hypokalemic activities of Bumetanide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide.
AliskirenThe risk or severity of adverse effects can be increased when Bumetanide is combined with Aliskiren.
AllopurinolThe risk or severity of adverse effects can be increased when Bumetanide is combined with Allopurinol.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bumetanide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Bumetanide.
AmcinonideAmcinonide may increase the hypokalemic activities of Bumetanide.
AmikacinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amikacin.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bumetanide.
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Bumetanide.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bumetanide.
AmobarbitalAmobarbital may increase the hypotensive activities of Bumetanide.
Amyl NitriteThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the diuretic activities of Bumetanide.
ApraclonidineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Apraclonidine.
ApremilastApremilast may decrease the diuretic activities of Bumetanide.
ArbutamineArbutamine may increase the hypokalemic activities of Bumetanide.
ArformoterolArformoterol may increase the hypokalemic activities of Bumetanide.
AripiprazoleAripiprazole may increase the hypotensive activities of Bumetanide.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bumetanide.
AzapropazoneAzapropazone may decrease the diuretic activities of Bumetanide.
AzelastineAzelastine may decrease the diuretic activities of Bumetanide.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Azilsartan medoxomil.
BalsalazideBalsalazide may decrease the diuretic activities of Bumetanide.
BambuterolBambuterol may increase the hypokalemic activities of Bumetanide.
BarbitalBarbital may increase the hypotensive activities of Bumetanide.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Bumetanide.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Bumetanide.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bumetanide.
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Bumetanide.
BetamethasoneBetamethasone may increase the hypokalemic activities of Bumetanide.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bumetanide.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Bumetanide.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bumetanide.
BretyliumThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Bumetanide.
BromfenacBromfenac may decrease the diuretic activities of Bumetanide.
BudesonideBudesonide may increase the hypokalemic activities of Bumetanide.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Bumetanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bumetanide.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bumetanide.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Bumetanide.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Bumetanide.
CandoxatrilBumetanide may increase the hypotensive activities of Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Captopril.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Bumetanide.
CarprofenCarprofen may decrease the diuretic activities of Bumetanide.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Bumetanide.
CarvedilolThe risk or severity of adverse effects can be increased when Bumetanide is combined with Carvedilol.
CastanospermineCastanospermine may decrease the diuretic activities of Bumetanide.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Bumetanide.
CelecoxibCelecoxib may decrease the diuretic activities of Bumetanide.
CeliprololCeliprolol may increase the hypokalemic activities of Bumetanide.
ChloroquineChloroquine may decrease the diuretic activities of Bumetanide.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bumetanide.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bumetanide.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bumetanide.
CholestyramineCholestyramine can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Bumetanide.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Bumetanide.
CilazaprilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Cilazapril.
CisplatinBumetanide may increase the nephrotoxic activities of Cisplatin.
ClenbuterolClenbuterol may increase the hypokalemic activities of Bumetanide.
ClevidipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clevidipine.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Bumetanide.
ClocortoloneClocortolone may increase the hypokalemic activities of Bumetanide.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Bumetanide.
ClonixinClonixin may decrease the diuretic activities of Bumetanide.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Bumetanide.
ColesevelamColesevelam can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Bumetanide.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.
D-LimoneneD-Limonene may decrease the diuretic activities of Bumetanide.
DapagliflozinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dapagliflozin.
DaunorubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Daunorubicin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Bumetanide.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Bumetanide.
DeslanosideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Bumetanide.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Bumetanide.
DexamethasoneDexamethasone may increase the hypokalemic activities of Bumetanide.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Bumetanide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bumetanide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bumetanide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bumetanide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bumetanide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Bumetanide.
DiclofenacDiclofenac may decrease the diuretic activities of Bumetanide.
DiclofenamideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Diclofenamide.
DiflorasoneDiflorasone may increase the hypokalemic activities of Bumetanide.
DiflunisalDiflunisal may decrease the diuretic activities of Bumetanide.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Bumetanide.
DifluprednateDifluprednate may increase the hypokalemic activities of Bumetanide.
DigitoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bumetanide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bumetanide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bumetanide.
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dihydrostreptomycin.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Bumetanide.
DinutuximabThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bumetanide.
DipivefrinDipivefrin may increase the hypokalemic activities of Bumetanide.
DipyridamoleThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dipyridamole.
DobutamineDobutamine may increase the hypokalemic activities of Bumetanide.
DofetilideBumetanide may increase the QTc-prolonging activities of Dofetilide.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bumetanide.
DoxorubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Doxorubicin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Bumetanide.
DroxicamDroxicam may decrease the diuretic activities of Bumetanide.
DroxidopaDroxidopa may increase the hypokalemic activities of Bumetanide.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Bumetanide.
DuloxetineBumetanide may increase the orthostatic hypotensive activities of Duloxetine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Bumetanide.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bumetanide.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Bumetanide.
EnalaprilatBumetanide may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Bumetanide.
EpinephrineEpinephrine may increase the hypokalemic activities of Bumetanide.
EpirizoleEpirizole may decrease the diuretic activities of Bumetanide.
EpirubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Epirubicin.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Bumetanide.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bumetanide.
EquileninEquilenin may increase the hypokalemic activities of Bumetanide.
EquilinEquilin may increase the hypokalemic activities of Bumetanide.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bumetanide.
EstroneEstrone may increase the hypokalemic activities of Bumetanide.
Etacrynic acidThe risk or severity of adverse effects can be increased when Bumetanide is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the diuretic activities of Bumetanide.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bumetanide.
EtodolacEtodolac may decrease the diuretic activities of Bumetanide.
EtofenamateEtofenamate may decrease the diuretic activities of Bumetanide.
EtoricoxibEtoricoxib may decrease the diuretic activities of Bumetanide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Bumetanide.
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Bumetanide.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Bumetanide.
exisulindexisulind may decrease the diuretic activities of Bumetanide.
FelodipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.
FenbufenFenbufen may decrease the diuretic activities of Bumetanide.
FenoprofenFenoprofen may decrease the diuretic activities of Bumetanide.
FenoterolFenoterol may increase the hypokalemic activities of Bumetanide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bumetanide.
FloctafenineFloctafenine may decrease the diuretic activities of Bumetanide.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Bumetanide.
FlumethasoneFlumethasone may increase the hypokalemic activities of Bumetanide.
FlunisolideFlunisolide may increase the hypokalemic activities of Bumetanide.
FlunixinFlunixin may decrease the diuretic activities of Bumetanide.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Bumetanide.
FluocinonideFluocinonide may increase the hypokalemic activities of Bumetanide.
FluocortoloneFluocortolone may increase the hypokalemic activities of Bumetanide.
FluorometholoneFluorometholone may increase the hypokalemic activities of Bumetanide.
FluprednideneFluprednidene may increase the hypokalemic activities of Bumetanide.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Bumetanide.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Bumetanide.
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Bumetanide.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Bumetanide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Bumetanide.
FormoterolFormoterol may increase the hypokalemic activities of Bumetanide.
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Bumetanide.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bumetanide.
FosphenytoinFosphenytoin may decrease the diuretic activities of Bumetanide.
FramycetinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Framycetin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bumetanide.
GentamicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Gentamicin.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Bumetanide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Bumetanide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Bumetanide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Bumetanide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bumetanide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Bumetanide.
GuanfacineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Bumetanide.
HexobarbitalHexobarbital may increase the hypotensive activities of Bumetanide.
HMPL-004HMPL-004 may decrease the diuretic activities of Bumetanide.
HydralazineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Bumetanide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bumetanide.
Hygromycin BThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hygromycin B.
IbuprofenIbuprofen may decrease the diuretic activities of Bumetanide.
IbuproxamIbuproxam may decrease the diuretic activities of Bumetanide.
IcatibantIcatibant may decrease the diuretic activities of Bumetanide.
IdarubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Idarubicin.
IndacaterolIndacaterol may increase the hypokalemic activities of Bumetanide.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Bumetanide.
IndomethacinIndomethacin may decrease the diuretic activities of Bumetanide.
IndoprofenIndoprofen may decrease the diuretic activities of Bumetanide.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Bumetanide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Bumetanide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bumetanide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Bumetanide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bumetanide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bumetanide.
IrbesartanThe risk or severity of adverse effects can be increased when Bumetanide is combined with Irbesartan.
IsoetarineIsoetarine may increase the hypokalemic activities of Bumetanide.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Bumetanide.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bumetanide.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the diuretic activities of Bumetanide.
IsoxsuprineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide.
IvabradineBumetanide may increase the arrhythmogenic activities of Ivabradine.
KanamycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Kanamycin.
KebuzoneKebuzone may decrease the diuretic activities of Bumetanide.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Bumetanide.
KetoprofenKetoprofen may decrease the diuretic activities of Bumetanide.
KetorolacKetorolac may decrease the diuretic activities of Bumetanide.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Bumetanide.
LeflunomideLeflunomide may decrease the diuretic activities of Bumetanide.
LevobunololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Levobunolol.
LevodopaBumetanide may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bumetanide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bumetanide.
LicoriceLicorice may increase the hypokalemic activities of Bumetanide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Bumetanide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Bumetanide.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bumetanide.
LithiumThe serum concentration of Lithium can be decreased when it is combined with Bumetanide.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Bumetanide.
LornoxicamLornoxicam may decrease the diuretic activities of Bumetanide.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide.
LoxoprofenLoxoprofen may decrease the diuretic activities of Bumetanide.
LumiracoxibLumiracoxib may decrease the diuretic activities of Bumetanide.
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Bumetanide.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Bumetanide.
MasoprocolMasoprocol may decrease the diuretic activities of Bumetanide.
MecamylamineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Bumetanide.
MedrysoneMedrysone may increase the hypokalemic activities of Bumetanide.
Mefenamic acidMefenamic acid may decrease the diuretic activities of Bumetanide.
MelengestrolMelengestrol may increase the hypokalemic activities of Bumetanide.
MeloxicamMeloxicam may decrease the diuretic activities of Bumetanide.
MesalazineMesalazine may decrease the diuretic activities of Bumetanide.
MetamizoleMetamizole may decrease the diuretic activities of Bumetanide.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Bumetanide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Bumetanide.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Bumetanide.
MethohexitalMethohexital may increase the hypotensive activities of Bumetanide.
MethotrexateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Methotrexate.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bumetanide.
MethyldopaThe risk or severity of adverse effects can be increased when Bumetanide is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bumetanide.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Bumetanide.
MetipranololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Bumetanide.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bumetanide.
MetrizamideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metrizamide.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Bumetanide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Bumetanide.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Bumetanide.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Bumetanide.
MometasoneMometasone may increase the hypokalemic activities of Bumetanide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bumetanide.
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Bumetanide.
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Bumetanide.
NabumetoneNabumetone may decrease the diuretic activities of Bumetanide.
NadololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nadolol.
NaftifineNaftifine may decrease the diuretic activities of Bumetanide.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bumetanide.
NaproxenNaproxen may decrease the diuretic activities of Bumetanide.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Bumetanide.
NCX 4016NCX 4016 may decrease the diuretic activities of Bumetanide.
NebivololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nebivolol.
NeomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Neomycin.
NepafenacNepafenac may decrease the diuretic activities of Bumetanide.
NesiritideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nesiritide.
NetilmicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Netilmicin.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Bumetanide.
NicorandilNicorandil may increase the hypotensive activities of Bumetanide.
NifedipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Bumetanide.
NimesulideNimesulide may decrease the diuretic activities of Bumetanide.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bumetanide.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bumetanide.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bumetanide.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bumetanide.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Bumetanide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Bumetanide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bumetanide.
OlodaterolOlodaterol may increase the hypokalemic activities of Bumetanide.
OlopatadineOlopatadine may decrease the diuretic activities of Bumetanide.
OlsalazineOlsalazine may decrease the diuretic activities of Bumetanide.
OmapatrilatBumetanide may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Bumetanide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Bumetanide.
OrgoteinOrgotein may decrease the diuretic activities of Bumetanide.
OuabainThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ouabain.
OxaprozinOxaprozin may decrease the diuretic activities of Bumetanide.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bumetanide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bumetanide.
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Bumetanide.
PapaverineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Papaverine.
ParamethasoneParamethasone may increase the hypokalemic activities of Bumetanide.
ParecoxibParecoxib may decrease the diuretic activities of Bumetanide.
ParomomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Paromomycin.
PenbutololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bumetanide.
PentobarbitalPentobarbital may increase the hypotensive activities of Bumetanide.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Bumetanide.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bumetanide.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Bumetanide.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Bumetanide.
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Bumetanide.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Bumetanide.
PhenytoinPhenytoin may decrease the diuretic activities of Bumetanide.
PimecrolimusPimecrolimus may decrease the diuretic activities of Bumetanide.
PindololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bumetanide.
PirbuterolPirbuterol may increase the hypokalemic activities of Bumetanide.
PirfenidonePirfenidone may decrease the diuretic activities of Bumetanide.
PiroxicamPiroxicam may decrease the diuretic activities of Bumetanide.
PlicamycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Plicamycin.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Bumetanide.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Bumetanide.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Bumetanide.
PrednisolonePrednisolone may increase the hypokalemic activities of Bumetanide.
PrednisonePrednisone may increase the hypokalemic activities of Bumetanide.
PregnenolonePregnenolone may increase the hypokalemic activities of Bumetanide.
PrimidonePrimidone may increase the hypotensive activities of Bumetanide.
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Bumetanide.
ProcaterolProcaterol may increase the hypokalemic activities of Bumetanide.
PropacetamolPropacetamol may decrease the diuretic activities of Bumetanide.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Bumetanide.
PTC299PTC299 may decrease the diuretic activities of Bumetanide.
PuromycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Puromycin.
QuetiapineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Bumetanide.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Bumetanide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bumetanide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Bumetanide.
RescinnamineBumetanide may increase the hypotensive activities of Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bumetanide.
ResveratrolResveratrol may decrease the diuretic activities of Bumetanide.
RibostamycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ribostamycin.
RimexoloneRimexolone may increase the hypokalemic activities of Bumetanide.
RiociguatThe risk or severity of adverse effects can be increased when Bumetanide is combined with Riociguat.
RisperidoneBumetanide may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Bumetanide.
RofecoxibRofecoxib may decrease the diuretic activities of Bumetanide.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Bumetanide.
SalbutamolSalbutamol may increase the hypokalemic activities of Bumetanide.
SalicylamideSalicylamide may decrease the diuretic activities of Bumetanide.
Salicylic acidSalicylic acid may decrease the diuretic activities of Bumetanide.
SalmeterolSalmeterol may increase the hypokalemic activities of Bumetanide.
SalsalateSalsalate may decrease the diuretic activities of Bumetanide.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Bumetanide.
SecobarbitalSecobarbital may increase the hypotensive activities of Bumetanide.
SeratrodastSeratrodast may decrease the diuretic activities of Bumetanide.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Bumetanide.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Bumetanide.
SpectinomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Spectinomycin.
SpiraprilBumetanide may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bumetanide.
SRT501SRT501 may decrease the diuretic activities of Bumetanide.
StreptomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Streptomycin.
StreptozocinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide.
SulfasalazineSulfasalazine may decrease the diuretic activities of Bumetanide.
SulindacSulindac may decrease the diuretic activities of Bumetanide.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Bumetanide.
SulpirideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sulpiride.
SuprofenSuprofen may decrease the diuretic activities of Bumetanide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Bumetanide.
TelmisartanThe risk or severity of adverse effects can be increased when Bumetanide is combined with Telmisartan.
TemocaprilBumetanide may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the diuretic activities of Bumetanide.
TepoxalinTepoxalin may decrease the diuretic activities of Bumetanide.
TerazosinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Terazosin.
TerbutalineTerbutaline may increase the hypokalemic activities of Bumetanide.
TeriflunomideTeriflunomide may decrease the diuretic activities of Bumetanide.
ThiamylalThiamylal may increase the hypotensive activities of Bumetanide.
ThiopentalThiopental may increase the hypotensive activities of Bumetanide.
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Bumetanide.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Bumetanide.
TixocortolTixocortol may increase the hypokalemic activities of Bumetanide.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Bumetanide.
TobramycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tobramycin.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Bumetanide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bumetanide.
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Bumetanide.
TolmetinTolmetin may decrease the diuretic activities of Bumetanide.
TopiramateBumetanide may increase the hypokalemic activities of Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bumetanide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bumetanide.
TranilastTranilast may decrease the diuretic activities of Bumetanide.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Bumetanide.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bumetanide.
Trisalicylate-cholineTrisalicylate-choline may decrease the diuretic activities of Bumetanide.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Bumetanide.
ValdecoxibValdecoxib may decrease the diuretic activities of Bumetanide.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Bumetanide.
VilanterolVilanterol may increase the hypokalemic activities of Bumetanide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Bumetanide.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Bumetanide.
ZaltoprofenZaltoprofen may decrease the diuretic activities of Bumetanide.
ZileutonZileuton may decrease the diuretic activities of Bumetanide.
ZomepiracZomepirac may decrease the diuretic activities of Bumetanide.
Food Interactions
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Thakker RV: Chloride channels in renal disease. Adv Nephrol Necker Hosp. 1999;29:289-98. [PubMed:10561751 ]
  2. Karolyi L, Koch MC, Grzeschik KH, Seyberth HW: The molecular genetic approach to "Bartter's syndrome". J Mol Med (Berl). 1998 Apr;76(5):317-25. [PubMed:9587066 ]
  3. Thakker RV: The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis. Curr Opin Nephrol Hypertens. 1998 Jul;7(4):385-8. [PubMed:9690036 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Long P, Mercer A, Begum R, Stephens GJ, Sihra TS, Jovanovic JN: Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. doi: 10.1074/jbc.M805322200. Epub 2009 Jan 13. [PubMed:19141616 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A2
Uniprot ID:
P55011
Molecular Weight:
131445.825 Da
References
  1. Panet R, Marcus M, Atlan H: Overexpression of the Na(+)/K(+)/Cl(-) cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts. J Cell Physiol. 2000 Jan;182(1):109-18. [PubMed:10567922 ]
  2. Evans RL, Park K, Turner RJ, Watson GE, Nguyen HV, Dennett MR, Hand AR, Flagella M, Shull GE, Melvin JE: Severe impairment of salivation in Na+/K+/2Cl- cotransporter (NKCC1)-deficient mice. J Biol Chem. 2000 Sep 1;275(35):26720-6. [PubMed:10831596 ]
  3. Wall SM, Fischer MP, Mehta P, Hassell KA, Park SJ: Contribution of the Na+-K+-2Cl- cotransporter NKCC1 to Cl- secretion in rat OMCD. Am J Physiol Renal Physiol. 2001 May;280(5):F913-21. [PubMed:11292635 ]
  4. Akar F, Jiang G, Paul RJ, O'Neill WC: Contractile regulation of the Na(+)-K(+)-2Cl(-) cotransporter in vascular smooth muscle. Am J Physiol Cell Physiol. 2001 Aug;281(2):C579-84. [PubMed:11443057 ]
  5. Jiang G, Klein JD, O'Neill WC: Growth factors stimulate the Na-K-2Cl cotransporter NKCC1 through a novel Cl(-)-dependent mechanism. Am J Physiol Cell Physiol. 2001 Dec;281(6):C1948-53. [PubMed:11698253 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein kinase binding
Specific Function:
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral Cl(-) exit in NaCl absorbing epithelia (By similarity). Isoform 4 has no transport activity.
Gene Name:
SLC12A4
Uniprot ID:
Q9UP95
Molecular Weight:
120648.73 Da
References
  1. Jean-Xavier C, Pflieger JF, Liabeuf S, Vinay L: Inhibitory postsynaptic potentials in lumbar motoneurons remain depolarizing after neonatal spinal cord transection in the rat. J Neurophysiol. 2006 Nov;96(5):2274-81. Epub 2006 Jun 28. [PubMed:16807348 ]
  2. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein kinase binding
Specific Function:
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in neurons.
Gene Name:
SLC12A5
Uniprot ID:
Q9H2X9
Molecular Weight:
126182.49 Da
References
  1. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO1. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation.
Gene Name:
CFTR
Uniprot ID:
P13569
Molecular Weight:
168139.895 Da
References
  1. Reddy MM, Quinton PM: Bumetanide blocks CFTR GCl in the native sweat duct. Am J Physiol. 1999 Jan;276(1 Pt 1):C231-7. [PubMed:9886939 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Cheng HF, Wang JL, Zhang MZ, McKanna JA, Harris RC: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest. 2000 Sep;106(5):681-8. [PubMed:10974021 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Hagenbuch B, Stieger B, Foguet M, Lubbert H, Meier PJ: Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10629-33. [PubMed:1961729 ]
  2. Platte HD, Honscha W, Schuh K, Petzinger E: Functional characterization of the hepatic sodium-dependent taurocholate transporter stably transfected into an immortalized liver-derived cell line and V79 fibroblasts. Eur J Cell Biol. 1996 May;70(1):54-60. [PubMed:8738419 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739 ]
  2. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Horz JA, Honscha W, Petzinger E: Bumetanide is not transported by the Ntcp or by the oatp: evidence for a third organic anion transporter in rat liver cells. Biochim Biophys Acta. 1996 Apr 19;1300(2):114-8. [PubMed:8652636 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23